TABLE 2.
ICV administration of tolbutamide decreases glucose infusion rate during hyperinsulinemic-euglycemic clamp conditions
| At Baseline |
During Clamp Conditions |
|||
| ICV Vehicle | ICV Tolbutamide | ICV Vehicle | ICV Tolbutamide | |
| Glucose (mmol/l) | 7.3 ± 1.3 | 7.3 ± 1.0 | 6.1 ± 0.4 | 6.7 ± 1.3 |
| TG (mmol/l) | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 |
| FFA (mmol/l) | 0.9 ± 0.1 | 0.8 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 |
| Insulin (ng/ml) | 0.3 ± 0.1 | 0.2 ± 0.1 | 4.4 ± 1.5 | 4.1 ± 0.8 |
| GIR (μmol/kg.min) | – | – | 114 ± 5.7 | 89 ± 3.2a |
| Hematocrit (%) | 43 ± 2 | 42 ± 2 | 42 ± 2 | 41 ± 2 |
| Half-life [14C]FA (min) | – | – | 0.5 ± 0.1 | 0.7 ± 0.1 |
| Half-life [3H]TG (min) | – | – | 1.4 ± 0.1 | 1.7 ± 0.1 |
Plasma parameters of mice that received ICV infusion of vehicle or tolbutamide at baseline and during hyperinsulinemic conditions. Values are means ± SEM for at least nine mice per group. GIR, glucose infusion rate.
aP < 0.05 versus vehicle.